Connection

Daniel Judge to RNAi Therapeutics

Back to Details
This is a "connection" page, showing publications Daniel Judge has written about RNAi Therapeutics.
Daniel Judge
Connection Strength
0.722
RNAi Therapeutics
  1. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.722
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.